Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00017407 | Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer | PHASE3 | COMPLETED | - | — | — | Oct 13, 2000 | Sep 9, 2002 | Dec 5, 2022 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| ISIS 3521 | BIOLOGICAL | - |
| carboplatin | DRUG | - |
| paclitaxel | DRUG | - |
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) Stage IV OR Stage IIIB with malignant pleural or pericardial effusion At least 1 unidimensionally measurable lesion At least 10 mm by spiral CT scan OR At least 20 mm by standard techniques OR Evalu...